Pfizer Inc. (NYSE: PFE) presented detailed results from an ongoing Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE